ANTITUMOR PROPERTIES OF DISCODERMOLIDE AND DERIVATIVES

Information

  • Research Project
  • 2837739
  • ApplicationId
    2837739
  • Core Project Number
    R01CA074227
  • Full Project Number
    5R01CA074227-02
  • Serial Number
    74227
  • FOA Number
  • Sub Project Id
  • Project Start Date
    12/9/1997 - 26 years ago
  • Project End Date
    11/30/2000 - 23 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    12/1/1998 - 25 years ago
  • Budget End Date
    11/30/1999 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    2
  • Suffix
  • Award Notice Date
    12/3/1998 - 25 years ago

ANTITUMOR PROPERTIES OF DISCODERMOLIDE AND DERIVATIVES

DESCRIPTION: The overall objective of the proposed project is to investigate the in vitro and in vivo antitumor properties of discodermolide, a marine-derived, microtubule interactive compound, and to prepare and analyze the antitumor activity of natural and synthetic derivatives, intermediates and analogs that have the potential of becoming efficacious therapeutic agents useful in the treatment of human cancer. Discodermolide's mechanism of action, which is similar to that of the chemically unrelated antitumor agent, taxol, includes the ability to block cellular proliferation at the G2/M phase of the cell cycle and to induce the premature polymerization of tubulin resulting in the formation of non-functional, microtubule "bundles," resulting in cell death. Discodermolide is active in vivo in i.p./i.p. P388 murine leukemia and in i.v./s.c. human ovarian tumor xenograft models. For the 3-year period, the principal proposes to: 1) isolate natural discodermolide analogs and prepare synthetic derivatives/intermediates and analogs of the compound, 2) utilize cytotoxicity, cell cycle, apoptosis, polymerization of purified tubulin, microtubule "bundling" assays and multi-drug resistant cell lines to identify their in vitro activities and to guide our chemical and synthetic efforts, 3) evaluate the in vivo activity of compounds selected on the basis of their in vitro activity in human tumor xenograft models of lung, breast and ovarian cancers. Successful completion of the proposed research will lead to: 1) the discovery of new discodermolide analogs and compounds which will be derived from natural discodermolide or from synthetic intermediates and/or analogs which may prove more efficacious than taxol, 2) improve the efficiency of various synthetic routes by which we obtain discodermolide which will provide increased amounts of compound for anticipated pre-clinical and eventual clinical development, and 3) provide possible insight into the structure activity relationship of discodermolide and its associated binding site.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    BNP
  • Study Section Name
    Bio-Organic and Natural Products Chemistry Study Section
  • Organization Name
    HARBOR BRANCH OCEANOGRAPHIC INST, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    FORT PIERCE
  • Organization State
    FL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    349467331
  • Organization District
    UNITED STATES